Vetta Francesco, Marinaccio Leonardo, Vetta Giampaolo, Marchese Domenico
Saint Camillus International University of Health Sciences, Rome, Italy.
Department of Cardiology, Immacolata Concezione Hospital, Piove di Sacco, Italy.
SAGE Open Med Case Rep. 2020 Nov 16;8:2050313X20974217. doi: 10.1177/2050313X20974217. eCollection 2020.
Hydroxychloroquine (HCQ) is a widely used drug to treat patients with coronavirus disease 19 (COVID-19). Although evidence of its efficacy and safety remains limited and controversial, both cardiac and non-cardiac adverse events are known to be associated with its use. To our knowledge, electrical storm in patients with COVID-19, or in any case treated with HCQ, has not been reported. We report the case of a 78-year-old male with an implantable cardiac resynchronization defibrillator (CRT-D) and a non-severe form of COVID-19. After a few days of home therapy with HCQ, an electrical storm was revealed that was associated with an increase in QTc. Following admission to the intensive care unit, HCQ was discontinued and progressive reduction of the QTc with electrical stabilization was observed. This clinical case highlights the potential risk of arrythmia associated with the use of HCQ and stresses the need for close electrocardiographic monitoring, especially in patients with established heart disease.
羟氯喹啉（HCQ）是一种广泛用于治疗新型冠状病毒肺炎（COVID-19）患者的药物。尽管其有效性和安全性的证据仍然有限且存在争议，但已知其使用会伴有心脏和非心脏不良事件。据我们所知，尚未有关于COVID-19患者或任何接受HCQ治疗的患者发生电风暴的报道。我们报告了一例78岁男性患者，他植入了心脏再同步除颤器（CRT-D），患有非重症COVID-19。在家接受HCQ治疗几天后，出现了与QTc延长相关的电风暴。入住重症监护病房后，停用了HCQ，观察到QTc逐渐缩短且电活动趋于稳定。该临床病例突出了使用HCQ相关的心律失常潜在风险，并强调了密切心电图监测的必要性，尤其是对于已有心脏病的患者。
